Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.
Clinical Trials
Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting
Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.
Opdivo, Opdualag Still Benefits Patients With Melanoma at 2 Years
After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.
Trial Will Evaluate Frontline Treatment With Lifileucel in Melanoma
The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”